Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism
Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Magnus Ingelman‐Sundberg(Karolinska Institutet), Lauri Kajosaari(University of Helsinki), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), Pertti J. Neuvonen(University of Helsinki), Mikko Niemi(University of Helsinki), Janne T. Backman(University of Helsinki)
Cited by 69
Related Papers
Metabolic gene polymorphism frequencies in control populations.
|PubMed|2001|847
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394